HK1194072A1 - Pyridazinone compounds and their use as daao inhibitors daao(d-) - Google Patents

Pyridazinone compounds and their use as daao inhibitors daao(d-)

Info

Publication number
HK1194072A1
HK1194072A1 HK14107513.7A HK14107513A HK1194072A1 HK 1194072 A1 HK1194072 A1 HK 1194072A1 HK 14107513 A HK14107513 A HK 14107513A HK 1194072 A1 HK1194072 A1 HK 1194072A1
Authority
HK
Hong Kong
Prior art keywords
daao
inhibitors
pyridazinone compounds
pyridazinone
compounds
Prior art date
Application number
HK14107513.7A
Other languages
English (en)
Chinese (zh)
Inventor
William Farnaby
Charlotte Fieldhouse
Katherine Hazel
Catrina Kerr
Natasha Kinsella
David Livermore
Kevin Merchant
David Miller
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1114399.7A external-priority patent/GB201114399D0/en
Priority claimed from GB201118658A external-priority patent/GB201118658D0/en
Priority claimed from GBGB1203533.3A external-priority patent/GB201203533D0/en
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of HK1194072A1 publication Critical patent/HK1194072A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • C07D237/16Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK14107513.7A 2011-08-22 2014-07-23 Pyridazinone compounds and their use as daao inhibitors daao(d-) HK1194072A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1114399.7A GB201114399D0 (en) 2011-08-22 2011-08-22 Novel compounds
GB201118658A GB201118658D0 (en) 2011-10-27 2011-10-27 Novel compounds
GBGB1203533.3A GB201203533D0 (en) 2012-02-29 2012-02-29 Novel compounds
PCT/GB2012/000672 WO2013027000A1 (en) 2011-08-22 2012-08-21 Pyridazinone compounds and their use as daao inhibitors

Publications (1)

Publication Number Publication Date
HK1194072A1 true HK1194072A1 (en) 2014-10-10

Family

ID=46758786

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14107513.7A HK1194072A1 (en) 2011-08-22 2014-07-23 Pyridazinone compounds and their use as daao inhibitors daao(d-)

Country Status (38)

Country Link
US (6) US9290456B2 (ru)
EP (1) EP2748149B9 (ru)
JP (1) JP6022573B2 (ru)
KR (1) KR101961851B1 (ru)
CN (1) CN103748079B (ru)
AP (1) AP2014007512A0 (ru)
AR (2) AR087607A1 (ru)
AU (1) AU2012298335B2 (ru)
BR (1) BR112014003906B1 (ru)
CA (1) CA2846204C (ru)
CL (1) CL2014000395A1 (ru)
CO (1) CO6910197A2 (ru)
CR (1) CR20140133A (ru)
CY (1) CY1117105T1 (ru)
DK (1) DK2748149T5 (ru)
DO (1) DOP2014000036A (ru)
EA (1) EA024956B1 (ru)
EC (1) ECSP14013215A (ru)
ES (1) ES2559631T3 (ru)
GE (1) GEP20156372B (ru)
HK (1) HK1194072A1 (ru)
HR (1) HRP20151310T2 (ru)
HU (1) HUE026691T2 (ru)
IL (1) IL230143A (ru)
JO (1) JO3115B1 (ru)
ME (1) ME02319B (ru)
MX (1) MX2014000783A (ru)
MY (1) MY180618A (ru)
PE (1) PE20141208A1 (ru)
PL (1) PL2748149T3 (ru)
PT (1) PT2748149E (ru)
RS (1) RS54515B9 (ru)
SI (1) SI2748149T1 (ru)
SM (1) SMT201600023B (ru)
TW (1) TWI546289B (ru)
UY (1) UY34280A (ru)
WO (1) WO2013027000A1 (ru)
ZA (1) ZA201400153B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009311667B2 (en) 2008-11-07 2016-04-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
UA119028C2 (uk) 2011-10-27 2019-04-25 Массачусеттс Інстітьют Оф Текнолоджі Функціоналізовані на n-кінці амінокислотні похідні, здатні утворювати мікросфери, що інкапсулюють лікарський засіб
US9212147B2 (en) 2011-11-15 2015-12-15 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
WO2014025993A1 (en) 2012-08-08 2014-02-13 The Johns Hopkins University Inhibitors of d-amino acid oxidase
GB201222711D0 (en) * 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US9956113B2 (en) 2013-03-12 2018-05-01 The Board Of Trustees Of The Leland Stanford Junior University Method and system for regulating core body temperature
GB201403944D0 (en) * 2014-03-06 2014-04-23 Takeda Pharmaceutical New use
IL248567B (en) * 2014-04-30 2022-08-01 Univ Nat Taiwan Use of compounds known as d-amino acid oxidase inhibitors
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
WO2019043635A1 (en) 2017-09-01 2019-03-07 Richter Gedeon Nyrt. COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE
US10336724B2 (en) * 2017-10-18 2019-07-02 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
CN109725092A (zh) * 2019-03-19 2019-05-07 北京和合医学诊断技术股份有限公司 检测血液中齐拉西酮含量的液相色谱分析方法
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
AU2022228417A1 (en) 2021-03-01 2023-10-26 Neurocrine Biosciences, Inc. Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU75958A1 (ru) 1976-10-08 1978-05-16
CH636632A5 (de) 1976-10-08 1983-06-15 Ciba Geigy Ag Neues verfahren zur herstellung von schwermetallkomplexen.
GB2025416A (en) 1978-07-14 1980-01-23 Pfizer Ltd Mercaptopyridazinethione antifungal agents
GB8421427D0 (en) 1984-08-23 1984-09-26 Smith Kline French Lab Chemical compounds
US4743685A (en) 1985-09-26 1988-05-10 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines
EG18314A (en) 1985-09-26 1993-02-28 Squibb & Sons Inc Process for preparing of 2-oxo-1((substituted sulfonyl)amino)carbonyl)-azitidines
DK170088A (da) 1987-04-10 1988-10-11 Hoffmann La Roche Acylderivater
WO1989000423A1 (en) 1987-07-09 1989-01-26 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
JPH01202875A (ja) 1988-02-09 1989-08-15 Fujitsu Ltd 超伝導材料構造の製造方法
US5244890A (en) 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
ES2077183T3 (es) 1990-11-22 1995-11-16 Cerestar Holding Bv Procedimiento para la produccion de chocolate.
EP0544166A3 (en) 1991-11-26 1993-11-03 Hoffmann La Roche Cephalosporinderivatives
GB9219313D0 (en) 1992-09-11 1992-10-28 Kodak Ltd Method of forming a photographic colour image
EP0724573A1 (en) 1993-10-20 1996-08-07 PHARMACIA & UPJOHN COMPANY Pyrimidinones as antiarthritic and anti-inflammatories
MX9701292A (es) 1994-08-24 1997-05-31 Astra Ab Compuestos espiro-azabiciclicos utiles en la terapia.
JPH092534A (ja) 1995-06-16 1997-01-07 Terada Seisakusho:Kk 茶貯蔵容器
JPH0925234A (ja) 1995-07-12 1997-01-28 Wakunaga Pharmaceut Co Ltd 脳疾患改善剤
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
US6525053B1 (en) 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
CA2299300C (en) 1997-08-22 2007-04-17 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
WO1999063989A1 (fr) 1998-06-10 1999-12-16 Meiji Seika Kaisha Ltd. Traitements de l'ataxie spinocerebelleuse et compositions utiles pour traiter l'ataxie spinocerebelleuse
CA2347982A1 (en) 1998-10-27 2000-05-04 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
JP2002028187A (ja) 2000-07-14 2002-01-29 Toto Ltd 車いす
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
WO2002020500A2 (en) 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
CN101486683B (zh) * 2000-09-18 2011-12-21 卫材R&D管理有限公司 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途
JP4137636B2 (ja) 2000-12-28 2008-08-20 塩野義製薬株式会社 カンナビノイド2型受容体親和作用を有するピリドン誘導体
KR100915263B1 (ko) 2001-05-18 2009-09-03 아스트라제네카 아베 4(페닐-피페라지닐-메틸)벤즈아미드 유도체 및 통증, 불안증 또는 위장관 장애 치료를 위한 이들의 용도
JP2004532877A (ja) 2001-06-01 2004-10-28 アストラゼネカ・アクチエボラーグ 治療に有効なニコチン性アセチルコリン受容体に対する新規なリガンド
WO2003047558A2 (en) 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
SI1466912T1 (sl) 2002-01-18 2013-08-30 Astellas Pharma Inc. Derivat 2-acilaminotiazola ali njegova sol
MXPA04010193A (es) 2002-04-18 2005-02-03 Astrazeneca Ab Compuesto de tienilo.
DE60328010D1 (de) 2002-04-18 2009-07-30 Astrazeneca Ab Heterocyclische verbindungen
WO2003087102A1 (en) 2002-04-18 2003-10-23 Astrazeneca Ab Furyl compounds
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
WO2004094408A1 (en) 2003-04-23 2004-11-04 Pharmacia & Upjohn Company Llc Substituted pyrimidinones and pyrimidinthiones as crf antagonists
CA2545659C (en) 2003-11-19 2013-06-04 Array Biopharma Inc. Bicyclic inhibitors of mek
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
CN1922149A (zh) * 2003-12-29 2007-02-28 塞普拉科公司 吡咯和吡唑daao抑制剂
US7915424B2 (en) 2004-03-22 2011-03-29 Eli Lilly And Company Pyridyl derivatives and their use as mGlu5 antagonists
US20070049611A1 (en) 2005-06-10 2007-03-01 Talamas Francisco X Phosphodiesterase 4 inhibitors
TWI375669B (en) 2006-03-17 2012-11-01 Sumitomo Chemical Co Pyridazinone compound and use thereof
MX2008016525A (es) * 2006-06-30 2009-03-09 Sepracor Inc Inhibidores heterocíclicos fusionados de d-amino ácido oxidasa.
US7579370B2 (en) 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
CA2676432A1 (en) 2007-01-18 2008-07-24 Sepracor, Inc. Inhibitors of d-amino acid oxidase
AR064962A1 (es) 2007-01-22 2009-05-06 Syngenta Participations Ag Derivados de piridazina utiles como fungicidas
KR20100049500A (ko) 2007-03-15 2010-05-12 쉐링 코포레이션 글루칸 신타제 억제제로서 유용한 피리다지논 유도체
MX2009010407A (es) 2007-03-28 2009-12-01 Apotex Technologies Inc Derivados fluorados de deferiprona.
WO2008156607A1 (en) * 2007-06-12 2008-12-24 Neurogen Corporation Substituted pyrimidinones
JP2009002534A (ja) 2007-06-19 2009-01-08 Denso Corp 熱交換器
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
US20100120740A1 (en) 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010058314A1 (en) * 2008-11-18 2010-05-27 Pfizer Inc. Hydroxyquinolin-2(1h)-ones and derivatives thereof
CN102365020B (zh) 2009-02-05 2014-07-30 武田药品工业株式会社 哒嗪酮化合物
US20130065857A1 (en) 2009-10-12 2013-03-14 Baylor College Of Medicine Novel dxr inhibitors for antimicrobial therapy
BR112012021652A2 (pt) 2010-03-04 2016-06-21 Merck Sharp & Dohme composto, uso do mesmo, e, composição farmacêutica
HUE036431T2 (hu) 2010-03-04 2018-07-30 Merck Sharp & Dohme Katechin o-metil transzferáz gátlók és alkalmazásuk pszichotikus betegségek kezelésében
MX2012010188A (es) 2010-03-04 2012-10-03 Merck Sharp & Dohme Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos.
US20120046232A1 (en) 2010-06-22 2012-02-23 Medical University Of South Carolina Compositions and methods for reducing relapse of addictive behavior
CA2840060A1 (en) 2011-06-27 2013-01-03 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9212147B2 (en) 2011-11-15 2015-12-15 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
US8868710B2 (en) 2011-11-18 2014-10-21 Amazon Technologies, Inc. Virtual network interface objects
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds

Also Published As

Publication number Publication date
IL230143A (en) 2017-03-30
JP6022573B2 (ja) 2016-11-09
TW201313687A (zh) 2013-04-01
HRP20151310T1 (en) 2016-01-01
ES2559631T3 (es) 2016-02-15
BR112014003906B1 (pt) 2022-03-22
HRP20151310T2 (hr) 2018-03-23
RS54515B9 (sr) 2020-12-31
CL2014000395A1 (es) 2014-12-05
IL230143A0 (en) 2014-03-06
KR101961851B1 (ko) 2019-03-26
DK2748149T3 (en) 2016-01-25
ECSP14013215A (es) 2014-05-31
AU2012298335B2 (en) 2017-06-01
US20220008416A1 (en) 2022-01-13
US11129828B2 (en) 2021-09-28
CN103748079B (zh) 2016-03-16
US20150030704A1 (en) 2015-01-29
US9290456B2 (en) 2016-03-22
ME02319B (me) 2016-06-20
PT2748149E (pt) 2016-02-04
ZA201400153B (en) 2015-12-23
US10463663B2 (en) 2019-11-05
CA2846204A1 (en) 2013-02-28
AP2014007512A0 (en) 2014-03-31
TWI546289B (zh) 2016-08-21
AR127309A2 (es) 2024-01-10
SMT201600023B (it) 2016-02-25
KR20140054297A (ko) 2014-05-08
CO6910197A2 (es) 2014-03-31
MX2014000783A (es) 2014-04-14
DOP2014000036A (es) 2014-06-30
PE20141208A1 (es) 2014-09-19
NZ620239A (en) 2015-10-30
CR20140133A (es) 2014-06-05
ES2559631T9 (es) 2018-03-13
CY1117105T1 (el) 2017-04-05
US9931340B2 (en) 2018-04-03
DK2748149T5 (en) 2017-04-24
CA2846204C (en) 2021-04-27
AR087607A1 (es) 2014-04-03
WO2013027000A1 (en) 2013-02-28
SI2748149T1 (sl) 2016-02-29
US20130052281A1 (en) 2013-02-28
PL2748149T3 (pl) 2016-04-29
CN103748079A (zh) 2014-04-23
MY180618A (en) 2020-12-03
JP2014524461A (ja) 2014-09-22
EA201490471A1 (ru) 2014-05-30
RS54515B1 (en) 2016-06-30
US20200121678A1 (en) 2020-04-23
GEP20156372B (en) 2015-09-25
BR112014003906A2 (pt) 2017-03-14
EP2748149A1 (en) 2014-07-02
EP2748149B1 (en) 2015-10-21
US20180177780A1 (en) 2018-06-28
JO3115B1 (ar) 2017-09-20
EP2748149B9 (en) 2017-11-15
US20170173007A1 (en) 2017-06-22
AU2012298335A1 (en) 2014-01-30
UY34280A (es) 2012-10-31
HUE026691T2 (hu) 2016-07-28
EA024956B1 (ru) 2016-11-30

Similar Documents

Publication Publication Date Title
HK1194072A1 (en) Pyridazinone compounds and their use as daao inhibitors daao(d-)
HK1257823A1 (zh) 金屬酶抑制劑化合物
HK1201519A1 (en) Inhibitors of phosphodiesterase type 10a 10a
HK1198163A1 (en) Metalloenzyme inhibitor compounds
HK1198651A1 (en) Metalloenzyme inhibitor compounds
GB2547788B (en) Releasable corrosion inhibitors
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
EP2723730A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
HK1198827A1 (en) Dyrk1 inhibitors and uses thereof dyrk1
HK1198157A1 (en) Urease inhibitor formulations
GB201016880D0 (en) Phosphodiesterase inhibitors
ZA201206456B (en) Uses of dgati inhibitors
IL228719A0 (en) parp inhibitors for the treatment of cipn
HUE038945T2 (hu) Piridazinonok mint DAAO enzim inhibitorok
EP2688901A4 (en) INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10
EP2751117A4 (en) METALLOENZYMHEMMERVERBINDUNGEN

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: TAKEDA PHARMACEUTICAL COMPANY LIMITED YRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS - REQUEST FOR CORRECTION ALLOWED ON 12.04.2018

Effective date: 20180412